Tasigna Indications/Uses

Treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Patients who have been treated with nilotinib (Tasigna) for at least 3 years and have achieved a sustained deep molecular response may be eligible for treatment discontinuation (see Dosage & Administrations).
Treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) in adult patients resistant to or intolerant to at least one prior therapy including imatinib. Ph+ CML patients in chronic phase, who have been previously treated with imatinib and whose treatment has been switched to nilotinib (Tasigna) for at least 3 years and have achieved a sustained deep molecular response may be eligible for treatment discontinuation (see Dosage & Administrations).
Treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Treatment of pediatric patients with chronic phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior therapy including imatinib.